pentadecapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Gabapentin enacarbil, sold under the brand name Horizant, among others, is an anticonvulsant and analgesic drug of the gabapentinoid class, and a prodrug to gabapentin. It was designed for increased oral bioavailability over gabapentin, and human trials showed it to produce extended release of gabapentin with almost twice the overall bioavailability, especially when taken with a fatty meal. Gabapentin enacarbil has passed human clinical trials for the treatment of restless legs syndrome, and initial results have shown it to be well tolerated and reasonably effective. Gabapentin enacarbil was denied approval by the US Food and Drug Administration (FDA) in February 2010, citing concerns about possible increased cancer risk shown by some animal studies. Similar concerns had been raised about gabapentin itself in the past, but were felt to be outweighed by its clinical utility as an anticonvulsant, whereas the treatment of restless legs syndrome was not seen to justify the same kind of risk. On 6 April 2011, Xenoport received FDA approval for Horizant (gabapentin enacarbil) for the treatment of moderate-to-severe restless legs syndrome. On 7 June 2012, the FDA approved Horizant for the treatment of postherpetic neuralgia in adults.
The yeast two-hybrid (Y2H) system, developed in the late 1980s and early 1990s, was an immense advancement in the use of reporter genes to study protein-protein interactions in vivo. This technique takes advantage of transcription factors' modular nature, which often consists of separate DNA-binding and activation domains. By genetically fusing two proteins of interest to these domains, researchers can detect physical interactions between them through the activation of a downstream reporter gene. Due to the simple genetic nature of the Y2H system, this technique significantly increased the accessibility of protein-protein interaction studies without the requirement of protein purification or complex biochemical assays. Experimental Y2H data have played a pivotal role in building large-scale synthetic human interactomes and in dissecting mechanisms in human disease. However, there are still some limitations. Y2H sometimes detects interactions that don't occur naturally or fails to detect weak or transient interactions. Due to its artificial setting, these failures could result from the absence of key factors such as post-translational modifications or compartmentalization. For example, Y2H has been shown to generate false positives due to indirect interactions mediated by host proteins, as demonstrated in studies of cyanobacterial PipX interactions where the self-interaction of PipX was found to be dependent on PII homologues from the host organism rather than a direct interaction.
Temperature swing solvent extraction is an experimental technique for the desalination of drinking water. It has been used to remove up to 98.5% of the salt content in water, and is able to process hypersaline brines that cannot be desalinated using reverse osmosis.
The atoms in a peptide link all lie on the same plane. The nitrogen, hydrogen, and oxygen atoms in a hydrogen bond are approximately in a straight line. The carbon-oxygen and nitrogen-hydrogen groups are all involved in bonding.
==== Aerospace ==== In April 1972 Heseltine was promoted to be minister for aerospace, a minister of state rather than a Cabinet minister but effectively running his own department within the Department of Trade and Industry, another of Heath's new mega ministries. The department had been given major new powers by the 1972 Industry Act. Later in the year Peter Walker was appointed Secretary of State for Trade and Industry, making him Heseltine's boss once again. Heseltine appointed Cecil Parkinson, whom he had met on an accountancy course in the mid-1950s, as his Parliamentary Private Secretary, ostensibly on the grounds that he knew even less about aerospace than he did. Parkinson was impressed by Heseltine's vigour and his insistence that civil servants produce results for him quickly, later writing in his memoirs (1992) "in his constructive and deliberate unreasonableness he reminds me in many ways of Mrs Thatcher". Heseltine arguably did not make aerospace policy any more interventionist than it already was. One of Heseltine's main jobs was to sell Concorde, which was difficult because of its cost and limited range (it could fly from New York to London or Paris, but not the short extra distance to Rome or Frankfurt) and capacity (a quarter that of a Boeing 747). It had been initiated by Macmillan in 1962 as an Anglo-French project to try to get Britain into the EEC, although by the early 1970s Heath was already broaching cancellation with President Pompidou.
Sources: en.wikipedia.org
== Function == Carboxypeptidase M is a membrane-bound arginine/lysine carboxypeptidase. This enzyme catalyses cleavage of C-terminal arginine or lysine residues from polypeptides. Its expression is associated with monocyte to macrophage differentiation. This encoded protein contains hydrophobic regions at the amino and carboxy termini and has 6 potential asparagine-linked glycosylation sites. The active site residues of carboxypeptidases A and B are conserved in this protein. Three alternatively spliced transcript variants encoding the same protein have been described for this gene.
Electrodes and Structural Transformations: During charge and discharge cycles, the materials in the anodes and cathodes undergo local structural transformations. These changes can be monitored using NMR by analyzing the signal's line shape, line intensity, and chemical shift. These transformations are often not captured by X-ray diffraction techniques (providing long-range information), making NMR indispensable for understanding the underlying mechanisms of energy storage. Metal Dendrite Formation: One of the challenges in lithium and sodium-based batteries is the formation of metal dendrites, which can lead to short circuits and catastrophic battery failure. In Situ NMR allows researchers to observe the formation of lithium or sodium dendrites in real time during battery cycling. Varying the cycling rates can also quantify the effect on dendrite formation, aiding in the development of strategies to suppress dendrite growth and reduce the risk of short circuits. Solid Electrolytes and Interfaces: Solid electrolytes, a key focus of next-generation battery research, often suffer from limited ion diffusion rates. NMR techniques can measure diffusivity in solid electrolytes, helping researchers understand how to enhance ion conductivity. Furthermore, NMR is used to study the Solid Electrolyte Interface (SEI), a layer that forms on the electrode surface and thus influences battery stability. Solid-state NMR (ssNMR) is particularly valuable for characterizing the composition and ion dynamics within the SEI layer due to its nondestructive testing capabilities.
Laserspray inlet ionization (LSII) is a subset of MAII and uses a matrix-assisted laser desorption/ionization (MALDI) method. It was originally called atmospheric pressure matrix-assisted laser desorption/ionization however was renamed as LSII to avoid confusion with MALDI and as it was found to be a type of inlet ionization. As all inlet ionization techniques, highly multiply charged ions are produced. A nitrogen laser is used to ablate the solid matrix/analyte into the heated inlet tube, the observed ions are generated at the surface of the matrix/analyte and so the laser is not directly involved in the ionization as was originally thought. LSII can determine protein molecular weights and has been found to detect masses of proteins up to 20,000 Da. The sensitivity of LSII, for protein detection, is higher by an order of magnitude compared to ESI.
== Classification of amines == Amines can be classified according to the nature and number of substituents on nitrogen. Aliphatic amines contain only H and alkyl substituents. Aromatic amines have the nitrogen atom connected to an aromatic ring.
Sources: en.wikipedia.org
== See also == Beaten coffee – Indian coffee beverage Caffè crema – Coffee drink Coffee portal Dalgona coffee – Whipped coffee drink Frappe (New England) – Cold dairy beveragePages displaying short descriptions of redirect targets Frappuccino – Starbucks iced coffee drink
==== Apixaban ==== The first full synthesis of apixaban was published in 2007. The key step of this reaction is a (3+2)cycloaddition of a p-methoxyphenylchlorohydrazon derivate and a p-iodophenyl-morpholin-dihydropyridin derivate. After the following elimination of HCl and morpholine, the iodine is substituted by 2-piperidinone by copper-catalization and the ethyl esther is converted to an amide (aminolysis). This reaction was registered as a patent in 2009.
== Education == Mezzenga was born in Terni, Italy. He studied materials science at the University of Perugia, where he obtained a Master of Science (MSc), cum laude, in 1997. His master's thesis, conducted in collaboration with the European Organization for Nuclear Research (CERN) and NASA in Houston, focused on interactions between polymers and elementary particles for application to the Alpha Magnetic Spectrometer. He completed his doctoral studies at the École Polytechnique Fédérale de Lausanne (EPFL) in 2001, working on polymer thermodynamic and earning a PhD in the field of Polymer Physics - Materials Science.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.